JANX

Janux Therapeutics Inc

JANX, USA

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.

https://www.januxrx.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
JANX
stock
JANX

Gains Recap: Will JANX outperform small cap indexes - 2025 Growth vs Value & Accurate Intraday Trade Tips baoquankhu1.vn

Read more →
JANX
stock
JANX

Clear Str Downgrades Janux Therapeutics (NASDAQ:JANX) to Hold MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$65.1177

Analyst Picks

Strong Buy

11

Buy

1

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.90

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-2.49 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-2.37 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-129.49 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.05

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 110.39% of the total shares of Janux Therapeutics Inc

1.

RA Capital Management, LLC

(18.6203%)

since

2025/06/30

2.

FMR Inc

(14.7914%)

since

2025/06/30

3.

HHG PLC

(7.4223%)

since

2025/06/30

4.

BlackRock Inc

(5.6625%)

since

2025/06/30

5.

Paradigm Biocapital Advisors LP

(4.8595%)

since

2025/06/30

6.

Adage Capital Partners Gp LLC

(4.2018%)

since

2025/06/30

7.

Fidelity Growth Compy Commingled Pl S

(3.6667%)

since

2025/07/31

8.

Vanguard Group Inc

(3.6433%)

since

2025/06/30

9.

Point72 Asset Management, L.P.

(3.5676%)

since

2025/06/30

10.

T. Rowe Price Associates, Inc.

(2.9844%)

since

2025/06/30

11.

Fidelity Growth Company Fund

(2.5978%)

since

2025/07/31

12.

Cormorant Asset Management, LLC

(2.4961%)

since

2025/06/30

13.

EcoR1 Capital, LLC

(2.4459%)

since

2025/06/30

14.

State Street Corp

(2.3099%)

since

2025/06/30

15.

Woodline Partners LP

(2.0667%)

since

2025/06/30

16.

Citadel Advisors Llc

(2.0487%)

since

2025/06/30

17.

Orbimed Advisors, LLC

(2.014%)

since

2025/06/30

18.

Vanguard Total Stock Mkt Idx Inv

(1.9569%)

since

2025/07/31

19.

Franklin Resources Inc

(1.7792%)

since

2025/06/30

20.

Logos Global Management LP

(1.6641%)

since

2025/06/30

21.

iShares Russell 2000 ETF

(1.5742%)

since

2025/08/31

22.

Geode Capital Management, LLC

(1.5015%)

since

2025/06/30

23.

Bank of America Corp

(1.4301%)

since

2025/06/30

24.

Prosight Management, LP

(1.4209%)

since

2025/06/30

25.

Fidelity Select Health Care

(1.1638%)

since

2025/07/31

26.

Fidelity Small Cap Growth

(1.1591%)

since

2025/06/30

27.

US Small-Cap Growth II Equity Comp

(1.0151%)

since

2025/06/30

28.

SPDR® S&P Biotech ETF

(0.9513%)

since

2025/08/31

29.

T. Rowe Price New Horizons

(0.8958%)

since

2025/07/31

30.

Janus Henderson Global Life Sciences

(0.8617%)

since

2025/06/30

31.

Janus Henderson Global Life Sciences D

(0.8617%)

since

2025/06/30

32.

Janus Henderson Triton D

(0.825%)

since

2025/06/30

33.

Janus Henderson US SMID Cap Growth

(0.825%)

since

2025/06/30

34.

Janus Henderson US SMID Cap Growth MA

(0.825%)

since

2025/06/30

35.

Fidelity Growth Company K6

(0.8039%)

since

2025/07/31

36.

Fidelity Advisor Health Care I

(0.7623%)

since

2025/07/31

37.

Janus Global Life Science AUSD

(0.7066%)

since

2025/06/30

38.

Janus Henderson Glb Life Scn I2 USD

(0.6998%)

since

2025/07/31

39.

Fidelity Small Cap Index

(0.6582%)

since

2025/06/30

40.

Fidelity Series Growth Company

(0.6513%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.6998

Latest Release

Date

2025-09-30

EPS Actual

-0.39

EPS Estimate

-0.6173

EPS Difference

0.2273

Surprise Percent

36.8216%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Possible Net-Net(4.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.